Atrial natriuretic prohormone peptides 1–30, 31–67, and 79–98 vasodilate the aorta

Dl, Vesely; Js, Norris; Jm, Walters; Rr, Jespersen; Da, Baeyens

doi:10.1016/s0006-291x(87)80307-8

Cited by 125 publications

(88 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vessel dilator is also known to be a potent venous dilator whose dilating effects do not require an intact endothelium and appear to be mediated via cGMP effects on the smooth muscle of blood vessels, including arterial (ie, aorta) smooth muscle. 25 Dilation of venous vessels decreases the capacitance of the venous system, resulting in decreased right atrial pressure. Because vessel dilator does decrease right atrial pressure in CHF, 19 this appears to be at least a partial cause of its beneficial hemodynamic effects in CHF.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure

et al. 1998

Self Cite

View full text Add to dashboard Cite

Background-Vessel dilator, a 37-amino acid peptide hormone synthesized in the heart, enhances urine flow 4-to 12-fold and sodium excretion 3-to 6-fold in healthy humans. The present investigation was designed to determine whether vessel dilator might have similar beneficial effects in persons with congestive heart failure (CHF). Methods and Results-Vessel dilator (100 ng/kg body weight per minute) given intravenously for 60 minutes to NYHA class III CHF subjects increased urine flow 2-to 13-fold, which was still increased (PϽ0.001) 3 hours after its infusion was stopped. Vessel dilator enhanced sodium excretion 3-to 4-fold in CHF subjects (PϽ0.01), which was still significantly (PϽ0.01) elevated 3 hours after infusion. Vessel dilator decreased systemic vascular resistance 24%, pulmonary vascular resistance 25%, pulmonary capillary wedge pressure 33%, and central venous pressure 27% while increasing cardiac output 34%, cardiac index 35%, and stroke volume index 24% without significantly affecting heart rate or pulmonary artery pressure in the CHF subjects. The control CHF patients did not have any changes in the above parameters. Conclusions-These results indicate that vessel dilator has significant beneficial diuretic, natriuretic, and hemodynamic properties in humans with congestive heart failure. (Circulation. 1998;98:323-329.)

show abstract

Section: Discussionmentioning

confidence: 99%

“…The decrease in systemic vascular resistance secondary to the arterial vasodilation 25 of vessel dilator also decreases the backpressure on the heart, resulting in decreased left atrial pressure. Systemic blood pressure and systemic vascular resistance were decreased, suggesting afterload and preload improvement with vessel dilator.…”

Section: Discussionmentioning

confidence: 99%

Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure

et al. 1998

Self Cite

View full text Add to dashboard Cite

show abstract

“…Within this 126-a.a. prohormone are several peptide hormones with blood pressure lowering, natriuretic, diuretic, and/or kaliuretic (i.e., potassium excreting) properties in both animals (20,21) and humans (22,23). These peptide hormones, numbered by their a.a. sequences beginning at the N-terminal end of the ANP prohormone, consist of the first 30 a.a. of the prohormone (i.e., long-acting natriuretic hormone;…”

Section: Gene Products Of the Proanp Genementioning

confidence: 99%

Atrial Natriuretic Peptide Prohormone Gene Expression: Hormones and Diseases That Upregulate its Expression

Vesely

2002

IUBMB Life

Self Cite

View full text Add to dashboard Cite

show abstract

“…1). The main physiological properties of these four peptide hormones after their release from the heart are blood pressure regulation and the maintenance of plasma volume in animals (Vesely et al 1987, Martin et al 1990, Gunning et al 1992, Benjamin & Peterson 1995, Zeidel 1995, Villarreal et al 1999, Dietz et al 2001 and humans (Vesely et al 1994a(Vesely et al ,b, 1998. The cardiac hormones, synthesized in the atrium of the heart, are long-acting natriuretic peptide (LANP) that consists of the first 30 a.a. from the N-terminal end of the ANP prohormone; vessel dilator, a.a. 31-67; kaliuretic peptide, a.a. 79-98; and ANP, a.a. 99-126 of the 126 a.a. prohormone (Vesely 1992(Vesely , 2002; Fig.…”

Section: Introductionmentioning

confidence: 99%

Cardiac hormones for the treatment of cancer

Vesely¹

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Four cardiac hormones, namely atrial natriuretic peptide, vessel dilator, kaliuretic peptide, and long-acting natriuretic peptide, reduce up to 97% of all cancer cells in vitro. These four cardiac hormones eliminate up to 86% of human small-cell lung carcinomas, two-thirds of human breast cancers, and up to 80% of human pancreatic adenocarcinomas growing in athymic mice. Their anticancer mechanisms of action, after binding to specific receptors on cancer cells, include targeting the rat sarcoma-bound GTP (RAS) (95% inhibition)-mitogen-activated protein kinase kinase 1/2 (MEK 1/2) (98% inhibition)-extracellular signal-related kinase 1/2 (ERK 1/2) (96% inhibition) cascade in cancer cells. They also inhibit MAPK9, i.e. c-Jun N-terminal kinase 2. They are dual inhibitors of vascular endothelial growth factor (VEGF) and its VEGFR2 receptor (up to 89%). One of the downstream targets of VEGF is b-catenin, which they reduce up to 88%. The WNT pathway is inhibited up to 68% and secreted frizzled-related protein 3 decreased up to 84% by the four cardiac hormones. AKT, a serine/threonine protein kinase, is reduced up to 64% by the cardiac hormones. STAT3, a final 'switch' that activates gene expression that leads to malignancy, is decreased by up to 88% by the cardiac hormones. STAT3 is specifically decreased as they do not affect STAT1. There is a cross-talk between the RAS-MEK 1/2-ERK 1/2 kinase cascade, VEGF, b-catenin, WNT, JNK, and STAT pathways and each of these pathways is inhibited by the cardiac hormones.

show abstract

Atrial natriuretic prohormone peptides 1–30, 31–67, and 79–98 vasodilate the aorta

Cited by 125 publications

References 12 publications

Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure

Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure

Atrial Natriuretic Peptide Prohormone Gene Expression: Hormones and Diseases That Upregulate its Expression

Cardiac hormones for the treatment of cancer

Contact Info

Product

Resources

About